271 related articles for article (PubMed ID: 22419876)
1. Physiologically based pharmacokinetic modeling of PLGA nanoparticles with varied mPEG content.
Li M; Panagi Z; Avgoustakis K; Reineke J
Int J Nanomedicine; 2012; 7():1345-56. PubMed ID: 22419876
[TBL] [Abstract][Full Text] [Related]
2. Effect of copolymer composition on the physicochemical characteristics, in vitro stability, and biodistribution of PLGA-mPEG nanoparticles.
Avgoustakis K; Beletsi A; Panagi Z; Klepetsanis P; Livaniou E; Evangelatos G; Ithakissios DS
Int J Pharm; 2003 Jun; 259(1-2):115-27. PubMed ID: 12787641
[TBL] [Abstract][Full Text] [Related]
3. Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA-mPEG nanoparticles.
Panagi Z; Beletsi A; Evangelatos G; Livaniou E; Ithakissios DS; Avgoustakis K
Int J Pharm; 2001 Jun; 221(1-2):143-52. PubMed ID: 11397575
[TBL] [Abstract][Full Text] [Related]
4. Preparation of DHAQ-loaded mPEG-PLGA-mPEG nanoparticles and evaluation of drug release behaviors in vitro/in vivo.
Duan Y; Sun X; Gong T; Wang Q; Zhang Z
J Mater Sci Mater Med; 2006 Jun; 17(6):509-16. PubMed ID: 16691348
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel-loaded PLGA and PLGA-PEG nanoparticles for intravenous application: pharmacokinetics and biodistribution profile.
Rafiei P; Haddadi A
Int J Nanomedicine; 2017; 12():935-947. PubMed ID: 28184163
[TBL] [Abstract][Full Text] [Related]
6. Design and Development of Bioceramic Based Functionalized PLGA Nanoparticles of Risedronate for Bone Targeting: In-vitro Characterization and Pharmacodynamic Evaluation.
Rawat P; Manglani K; Gupta S; Kalam A; Vohora D; Ahmad FJ; Talegaonkar S
Pharm Res; 2015 Oct; 32(10):3149-58. PubMed ID: 25840949
[TBL] [Abstract][Full Text] [Related]
7. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats.
Li Y; Pei Y; Zhang X; Gu Z; Zhou Z; Yuan W; Zhou J; Zhu J; Gao X
J Control Release; 2001 Apr; 71(2):203-11. PubMed ID: 11274752
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution properties of nanoparticles based on mixtures of PLGA with PLGA-PEG diblock copolymers.
Beletsi A; Panagi Z; Avgoustakis K
Int J Pharm; 2005 Jul; 298(1):233-41. PubMed ID: 15936907
[TBL] [Abstract][Full Text] [Related]
9. Definition of formulation design space, in vitro bioactivity and in vivo biodistribution for hydrophilic drug loaded PLGA/PEO-PPO-PEO nanoparticles using OFAT experiments.
Simonoska Crcarevska M; Geskovski N; Calis S; Dimchevska S; Kuzmanovska S; Petruševski G; Kajdžanoska M; Ugarkovic S; Goracinova K
Eur J Pharm Sci; 2013 Apr; 49(1):65-80. PubMed ID: 23439240
[TBL] [Abstract][Full Text] [Related]
10. Pegylated poly(lactide) and poly(lactide-co-glycolide) nanoparticles: preparation, properties and possible applications in drug delivery.
Avgoustakis K
Curr Drug Deliv; 2004 Oct; 1(4):321-33. PubMed ID: 16305394
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
12. Biodistribution and toxicity of orally administered poly (lactic-co-glycolic) acid nanoparticles to F344 rats for 21 days.
Navarro SM; Morgan TW; Astete CE; Stout RW; Coulon D; Mottram P; Sabliov CM
Nanomedicine (Lond); 2016 Jul; 11(13):1653-69. PubMed ID: 27347781
[TBL] [Abstract][Full Text] [Related]
13. The effect of nanoparticle properties, detection method, delivery route and animal model on poly(lactic-co-glycolic) acid nanoparticles biodistribution in mice and rats.
Simon LC; Sabliov CM
Drug Metab Rev; 2014 May; 46(2):128-41. PubMed ID: 24303927
[TBL] [Abstract][Full Text] [Related]
14. Preparation, characterization and uptake of PEG-coated, muco-inert nanoparticles in HGC-27 cells, a mucin-producing, gastric-cancer cell line.
Lin D; Li G; Qin L; Wen Z; Wang J; Sun X
J Biomed Nanotechnol; 2013 Dec; 9(12):2017-23. PubMed ID: 24266257
[TBL] [Abstract][Full Text] [Related]
15. The comparison of different daidzein-PLGA nanoparticles in increasing its oral bioavailability.
Ma Y; Zhao X; Li J; Shen Q
Int J Nanomedicine; 2012; 7():559-70. PubMed ID: 22346351
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of the biodistribution and safety of PLGA nanoparticles as drug delivery systems.
Semete B; Booysen L; Lemmer Y; Kalombo L; Katata L; Verschoor J; Swai HS
Nanomedicine; 2010 Oct; 6(5):662-71. PubMed ID: 20230912
[TBL] [Abstract][Full Text] [Related]
17. Development of PLGA-based itraconazole injectable nanospheres for sustained release.
Bian X; Liang S; John J; Hsiao CH; Wei X; Liang D; Xie H
Int J Nanomedicine; 2013; 8():4521-31. PubMed ID: 24311942
[TBL] [Abstract][Full Text] [Related]
18. Effects of protein binding on the biodistribution of PEGylated PLGA nanoparticles post oral administration.
Semete B; Booysen L; Kalombo L; Ramalapa B; Hayeshi R; Swai HS
Int J Pharm; 2012 Mar; 424(1-2):115-20. PubMed ID: 22227605
[TBL] [Abstract][Full Text] [Related]
19. [Transport of PLGA nanoparticles across Caco-2/HT29-MTX co-cultured cells].
Wen Z; Li G; Lin DH; Wang JT; Qin LF; Guo GP
Yao Xue Xue Bao; 2013 Dec; 48(12):1829-35. PubMed ID: 24689242
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution of indocyanine green-loaded nanoparticles with surface modifications of PEG and folic acid.
Ma Y; Sadoqi M; Shao J
Int J Pharm; 2012 Oct; 436(1-2):25-31. PubMed ID: 22692077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
